Literature DB >> 8666898

The function of the soluble interleukin 6 (IL-6) receptor in vivo: sensitization of human soluble IL-6 receptor transgenic mice towards IL-6 and prolongation of the plasma half-life of IL-6.

M Peters1, S Jacobs, M Ehlers, P Vollmer, J Müllberg, E Wolf, G Brem, K H Meyer zum Büschenfelde, S Rose-John.   

Abstract

Interleukin 6 (IL-6) is considered an important mediator of acute inflammatory responses. Moreover, IL-6 functions as a differentiation and growth factor of hematopoietic precursor cells, B cells, T cells, keratinocytes, neuronal cells, osteoclasts, and endothelial cells. IL-6 exhibits its action via a receptor complex consisting of a specific IL-6 receptor (IL-6R) and a signal transducing subunit (gp130). Soluble forms of both receptor components are generated by shedding and are found in patients with various diseases such as acquired immune deficiency syndrome, rheumatoid arthritis, and others. The function of the soluble (s)IL-6R in vivo is unknown. Since human (h)IL-6 acts on human and murine target cells, but murine IL-6 on murine cells only, we constructed transgenic mice expressing the hsIL-6R. We report here that in the presence of hsIL-6R, mice are hypersensitized towards hIL-6, mounting an acute phase protein gene induction at significantly lower IL-6 dosages compared to control animals. Furthermore, in hsIL-6R transgenic mice, the detected acute phase response persists for a longer period of time. The IL-6/IL-6R complex prolongs markedly the Il-6 plasma half-life. Our results reinforce the role of the hsIL-6R as an agonistic protein, help to understand the function of the hsIL-6R in vivo, and highlight the significance of the receptor in the induction of the acute phase response.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8666898      PMCID: PMC2192475          DOI: 10.1084/jem.183.4.1399

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  53 in total

Review 1.  Cytokine signal transduction.

Authors:  T Kishimoto; T Taga; S Akira
Journal:  Cell       Date:  1994-01-28       Impact factor: 41.582

2.  Identification of a region within the cytoplasmic domain of the interleukin-6 (IL-6) signal transducer gp130 important for ligand-induced endocytosis of the IL-6 receptor.

Authors:  E Dittrich; S Rose-John; C Gerhartz; J Müllberg; T Stoyan; K Yasukawa; P C Heinrich; L Graeve
Journal:  J Biol Chem       Date:  1994-07-22       Impact factor: 5.157

Review 3.  Soluble receptors for cytokines and growth factors: generation and biological function.

Authors:  S Rose-John; P C Heinrich
Journal:  Biochem J       Date:  1994-06-01       Impact factor: 3.857

4.  Serum soluble interleukin 6 (IL-6) receptor and IL-6/soluble IL-6 receptor complex in systemic juvenile rheumatoid arthritis.

Authors:  F De Benedetti; M Massa; P Pignatti; S Albani; D Novick; A Martini
Journal:  J Clin Invest       Date:  1994-05       Impact factor: 14.808

Review 5.  Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins.

Authors:  J E Darnell; I M Kerr; G R Stark
Journal:  Science       Date:  1994-06-03       Impact factor: 47.728

6.  Differential shedding of the two subunits of the interleukin-6 receptor.

Authors:  J Müllberg; E Dittrich; L Graeve; C Gerhartz; K Yasukawa; T Taga; T Kishimoto; P C Heinrich; S Rose-John
Journal:  FEBS Lett       Date:  1993-10-11       Impact factor: 4.124

7.  The soluble human IL-6 receptor. Mutational characterization of the proteolytic cleavage site.

Authors:  J Müllberg; W Oberthür; F Lottspeich; E Mehl; E Dittrich; L Graeve; P C Heinrich; S Rose-John
Journal:  J Immunol       Date:  1994-05-15       Impact factor: 5.422

8.  Recombinant soluble human interleukin-6 receptor. Expression in Escherichia coli, renaturation and purification.

Authors:  T Stoyan; U Michaelis; H Schooltink; M Van Dam; R Rudolph; P C Heinrich; S Rose-John
Journal:  Eur J Biochem       Date:  1993-08-15

9.  Soluble forms of the interleukin-6 signal-transducing receptor component gp130 in human serum possessing a potential to inhibit signals through membrane-anchored gp130.

Authors:  M Narazaki; K Yasukawa; T Saito; Y Ohsugi; H Fukui; Y Koishihara; G D Yancopoulos; T Taga; T Kishimoto
Journal:  Blood       Date:  1993-08-15       Impact factor: 22.113

10.  Soluble interleukin-6 receptor triggers osteoclast formation by interleukin 6.

Authors:  T Tamura; N Udagawa; N Takahashi; C Miyaura; S Tanaka; Y Yamada; Y Koishihara; Y Ohsugi; K Kumaki; T Taga
Journal:  Proc Natl Acad Sci U S A       Date:  1993-12-15       Impact factor: 11.205

View more
  73 in total

1.  Converting IL-15 to a superagonist by binding to soluble IL-15R{alpha}.

Authors:  Mark P Rubinstein; Marek Kovar; Jared F Purton; Jae-Ho Cho; Onur Boyman; Charles D Surh; Jonathan Sprent
Journal:  Proc Natl Acad Sci U S A       Date:  2006-06-06       Impact factor: 11.205

2.  IL-6 trans-signaling system in intra-amniotic inflammation, preterm birth, and preterm premature rupture of the membranes.

Authors:  Sarah Y Lee; Irina A Buhimschi; Antonette T Dulay; Unzila A Ali; Guomao Zhao; Sonya S Abdel-Razeq; Mert O Bahtiyar; Stephen F Thung; Edmund F Funai; Catalin S Buhimschi
Journal:  J Immunol       Date:  2011-01-31       Impact factor: 5.422

3.  Matrix metalloproteinase 8 contributes to solubilization of IL-13 receptor alpha2 in vivo.

Authors:  Weiguo Chen; Yasuhiro Tabata; Aaron M Gibson; Michael O Daines; Manoj R Warrier; Marsha Wills-Karp; Gurjit K Khurana Hershey
Journal:  J Allergy Clin Immunol       Date:  2008-08-09       Impact factor: 10.793

Review 4.  Lack of knowledge: breast cancer and the soluble interleukin-6 receptor.

Authors:  Heike Knüpfer; Rainer Preiss
Journal:  Breast Care (Basel)       Date:  2010-06       Impact factor: 2.860

Review 5.  Therapeutic strategies for the clinical blockade of IL-6/gp130 signaling.

Authors:  Simon A Jones; Jürgen Scheller; Stefan Rose-John
Journal:  J Clin Invest       Date:  2011-09-01       Impact factor: 14.808

6.  Retrograde inflammatory signaling from neutrophils to endothelial cells by soluble interleukin-6 receptor alpha.

Authors:  V Modur; Y Li; G A Zimmerman; S M Prescott; T M McIntyre
Journal:  J Clin Invest       Date:  1997-12-01       Impact factor: 14.808

7.  Hepatocellular hyperplasia, plasmacytoma formation, and extramedullary hematopoiesis in interleukin (IL)-6/soluble IL-6 receptor double-transgenic mice.

Authors:  P Schirmacher; M Peters; G Ciliberto; M Blessing; J Lotz; K H Meyer zum Büschenfelde; S Rose-John
Journal:  Am J Pathol       Date:  1998-08       Impact factor: 4.307

8.  Soluble IL7Rα potentiates IL-7 bioactivity and promotes autoimmunity.

Authors:  Wangko Lundström; Steven Highfill; Scott T R Walsh; Stephanie Beq; Elizabeth Morse; Ingrid Kockum; Lars Alfredsson; Tomas Olsson; Jan Hillert; Crystal L Mackall
Journal:  Proc Natl Acad Sci U S A       Date:  2013-04-22       Impact factor: 11.205

Review 9.  Cytokines in chronic rheumatic diseases: is everything lack of homeostatic balance?

Authors:  Carlo Chizzolini; Jean-Michel Dayer; Pierre Miossec
Journal:  Arthritis Res Ther       Date:  2009-10-14       Impact factor: 5.156

10.  Serum soluble glycoprotein 130 concentration is inversely related to insulin sensitivity in women with polycystic ovary syndrome.

Authors:  Agnieszka Nikolajuk; Irina Kowalska; Monika Karczewska-Kupczewska; Agnieszka Adamska; Elzbieta Otziomek; Slawomir Wolczynski; Ida Kinalska; Maria Gorska; Marek Straczkowski
Journal:  Diabetes       Date:  2010-01-26       Impact factor: 9.461

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.